Home Data Calendar Blog

YMAB

Tables

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31
Common Stock Value 0.000.000.000.000.000.000.000.000.000.000.000.00
Weighted Average Number Of Diluted Shares Outstanding 43.6243.6643.67NA43.7243.7243.71NA43.6043.5744.38NA
Weighted Average Number Of Shares Outstanding Basic 43.6243.6643.67NA43.7243.7243.71NA43.6043.5741.87NA
Earnings Per Share Basic -0.18-0.14-0.150.02-0.63-0.94-0.64-0.85-0.66-0.530.80-0.48
Earnings Per Share Diluted -0.18-0.14-0.150.02-0.63-0.94-0.64-0.85-0.66-0.530.75-0.48

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31
Revenue From Contract With Customer Excluding Assessed Tax 20.4520.7520.2531.4512.5410.8010.499.608.9610.955.3820.75
Revenues 20.4520.7520.2531.4512.5410.8010.499.608.9610.955.3820.75
Cost Of Goods And Services Sold 2.604.652.082.022.481.141.831.460.550.200.09NA
Costs And Expenses 28.2027.9727.7532.6038.5550.7438.1845.3637.6733.6633.6440.84
Research And Development Expense 15.3612.0513.4219.7922.4526.4222.9128.7623.1319.7821.5824.01
Selling General And Administrative Expense 10.2011.2712.2510.7913.6323.0813.4415.1413.9913.4711.9714.63
Operating Income Loss -7.75-7.22-7.50-1.15-26.02-39.95-27.70-35.76-28.70-22.71-28.26-20.09
Income Tax Expense Benefit 0.190.18NANANANANANANANANANA
Profit Loss -7.75-6.30-6.391.16-27.53-41.13-28.07-36.89-28.86-22.9433.41-19.93
Net Income Loss -7.75-6.30-6.391.16-27.53-41.13-28.07-36.89-28.86-22.9433.41-19.93
Comprehensive Income Net Of Tax -6.94-6.28-6.70-2.21-25.93-39.71-27.76-35.75-28.62-22.8633.85-20.43
Net Income Loss Available To Common Stockholders Basic -7.75-6.30-6.391.16-27.53-41.13-28.07-36.89-28.86-22.9433.41-19.93
Net Income Loss Available To Common Stockholders Diluted -7.75-6.30NA1.16-27.53-41.13-28.07-36.89-28.86-22.9433.41-19.93

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31
Assets 128.88132.40137.44141.46143.91165.18191.05212.78239.98259.48274.92132.05
Liabilities 28.7327.7129.6232.2336.0233.7833.5832.6829.1325.1622.7026.21
Liabilities And Stockholders Equity 128.88132.40137.44141.46143.91165.18191.05212.78239.98259.48274.92132.05
Stockholders Equity 100.15104.68107.83109.22107.90131.40157.47180.11210.84234.32252.22105.84

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31
Assets Current 114.86115.78124.01130.45133.24153.92177.74202.26230.58249.37264.01122.36
Cash And Cash Equivalents At Carrying Value 86.5787.9192.63105.76114.53133.66156.72181.56215.73233.59252.27114.63
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 86.5787.9192.63105.76114.53133.66156.72181.56215.73233.59252.27114.63
Accounts Receivable Net Current 18.8719.1218.7012.539.257.219.327.717.268.526.00NA
Inventory Net 7.115.198.956.706.246.795.595.514.793.821.00NA
Other Assets Current 2.303.573.735.453.236.256.107.472.803.444.747.73

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31
Property Plant And Equipment Net 0.300.380.510.601.371.551.701.851.851.922.101.82
Intangible Assets Net Excluding Goodwill 2.722.812.902.991.531.571.621.66NANANANA
Other Assets Noncurrent 9.4112.258.665.685.605.756.843.174.754.794.833.29

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31
Liabilities Current 21.8124.2325.9228.2832.0229.4529.0427.8825.3620.9917.0019.54
Accounts Payable Current 7.617.258.8414.1813.7211.2914.6613.5511.026.806.549.37
Other Accrued Liabilities Current 0.740.450.320.411.520.271.441.420.641.000.990.33
Accrued Liabilities Current 13.3016.1516.2213.2417.0917.0712.9312.5412.4912.178.498.20

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31
Other Liabilities Noncurrent 0.820.820.820.800.730.780.830.850.870.941.931.97
Operating Lease Liability Noncurrent 0.720.420.630.901.021.301.601.850.650.991.512.01

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31
Stockholders Equity 100.15104.68107.83109.22107.90131.40157.47180.11210.84234.32252.22105.84
Common Stock Value 0.000.000.000.000.000.000.000.000.000.000.000.00
Additional Paid In Capital 554.78552.37549.23543.93540.39537.96524.33519.21514.20509.05504.09391.56
Retained Earnings Accumulated Deficit -456.48-448.74-442.43-436.04-437.20-409.67-368.54-340.48-303.58-274.72-251.79-285.20
Accumulated Other Comprehensive Income Loss Net Of Tax 1.851.041.021.334.703.101.681.370.23-0.01-0.09-0.53

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31
Net Cash Provided By Used In Operating Activities -1.34-4.73-13.12-8.66-19.23-23.10-24.93-33.86-18.08-18.76-31.86-17.70
Net Cash Provided By Used In Financing Activities NANANA0.000.050.000.030.100.250.13107.831.42

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31
Net Cash Provided By Used In Operating Activities -1.34-4.73-13.12-8.66-19.23-23.10-24.93-33.86-18.08-18.76-31.86-17.70
Net Income Loss -7.75-6.30-6.391.16-27.53-41.13-28.07-36.89-28.86-22.9433.41-19.93
Profit Loss -7.75-6.30-6.391.16-27.53-41.13-28.07-36.89-28.86-22.9433.41-19.93
Depreciation Depletion And Amortization 0.170.220.180.230.230.190.200.290.140.220.130.12
Increase Decrease In Accounts Receivable -0.240.426.173.282.04-2.121.610.45-1.252.526.00NA
Increase Decrease In Inventories 1.93-3.762.240.46-0.551.210.080.720.972.811.00NA
Increase Decrease In Accounts Payable -0.05-1.38-4.77-1.092.43-3.371.112.534.220.26-2.83-0.95
Share Based Compensation 2.413.625.303.543.3413.635.094.914.904.834.708.34

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31
Net Cash Provided By Used In Financing Activities NANANA0.000.050.000.030.100.250.13107.831.42

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31
Revenues 20.4520.7520.2531.4512.5410.8010.499.608.9610.955.3820.75
Adium Pharma S.a, License Milestone, Distribution Arrangement NANANANANANANANANANANANA
Sciclone International Pharmaceuticals Ltd, License Milestone, Development And Commercialization Arrangement NANANA15.00NANANANANANANANA
Wep Clinical Limited, Product Danyelza NA2.52NANANANANANANANANANA
Wep Clinical Limited, Product, Non Us, Distribution Arrangement 3.05NANANANANANANANANANANA
Wep Clinical Limited, Product, Distribution Arrangement 3.05NANANANANANANANANANANA
License 0.50NANA15.000.001.00NA0.000.002.00NA20.00
Product 19.9520.75NA16.4512.549.80NA9.608.968.955.38NA
Product Danyelza 19.9520.7520.2516.4512.549.8010.499.718.858.955.40NA
Royalty, Sales Channel Through Intermediary 0.43NANANA0.06NANANANANANANA
Product Danyelza, Sales Channel Through Intermediary NA2.62NANANA0.74NANANANANANA
Product,US 16.07NANANA12.42NANANANANANANA
Product, Non Us 3.88NANANA0.12NANANANANANANA
Product Danyelza, NA3.54NANANANANANANANANANA
Product Danyelza, NA0.002.52NANANANANANANANANA
Product Danyelza,US NA15.85NANANA9.02NANANANANANA
Product Danyelza, Non Us NA4.90NANANA0.78NANANANANANA
US NANA16.83NANANANANANANANANA
Non Us NANA3.42NANANANANANANANANA
Revenue From Contract With Customer Excluding Assessed Tax 20.4520.7520.2531.4512.5410.8010.499.608.9610.955.3820.75
Adium Pharma S.a, License Milestone, Distribution Arrangement NANANANANANANANANANANANA
Sciclone International Pharmaceuticals Ltd, License Milestone, Development And Commercialization Arrangement NANANA15.00NANANANANANANANA
Wep Clinical Limited, Product Danyelza NA2.52NANANANANANANANANANA
Wep Clinical Limited, Product, Non Us, Distribution Arrangement 3.05NANANANANANANANANANANA
Wep Clinical Limited, Product, Distribution Arrangement 3.05NANANANANANANANANANANA
License 0.50NANA15.000.001.00NA0.000.002.00NA20.00
Product 19.9520.75NA16.4512.549.80NA9.608.968.955.38NA
Product Danyelza 19.9520.7520.2516.4512.549.8010.499.718.858.955.40NA
Royalty, Sales Channel Through Intermediary 0.43NANANA0.06NANANANANANANA
Product Danyelza, Sales Channel Through Intermediary NA2.62NANANA0.74NANANANANANA
Product,US 16.07NANANA12.42NANANANANANANA
Product, Non Us 3.88NANANA0.12NANANANANANANA
Product Danyelza, NA3.54NANANANANANANANANANA
Product Danyelza, NA0.002.52NANANANANANANANANA
Product Danyelza,US NA15.85NANANA9.02NANANANANANA
Product Danyelza, Non Us NA4.90NANANA0.78NANANANANANA
US NANA16.83NANANANANANANANANA
Non Us NANA3.42NANANANANANANANANA

Plots across concepts


IncomeStatement
Operating Income Loss
Expenses
Income Tax Expense Benefit
Balance Sheet
Operating Lease Right Of Use Asset
Assets
Property Plant And Equipment Net
Current Assets
Other Assets Current
NonCurrent Assets
Property Plant And Equipment Net
Liabilities
Operating Lease Liability
Current Liabilities
Other Accrued Liabilities Current
Stockholders Equity
Retained Earnings Accumulated Deficit
CashFlow
Net Income Loss
NetCashProvidedByUsedInOperatingActivities
Net Income Loss
Shares
Weighted Average Number Of Shares Outstanding Basic
OperatingLeaseLiability
Operating Lease Liability Noncurrent
LesseeOperatingLeaseLiabilityPaymentsDue
Lessee Operating Lease Liability Undiscounted Excess Amount
InventoryNet
Inventory Raw Materials Net Of Reserves

Line plots across dimensions of each concept


TTM Greenblatt ROC
_
(None,)
T T M Greenblatt R O C_
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:StatementGeographical
('ymab:ProductDanyelza', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Statement Geographical
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:ContractWithCustomerSalesChannel
(None, 'us-gaap:SalesChannelThroughIntermediary')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Contract With Customer Sales Channel
us-gaap:Revenues
us-gaap:ProductOrService
(None,)
Revenuesus-gaap: Product Or Service
us-gaap:Revenues
us-gaap:ProductOrService, us-gaap:StatementGeographical
('ymab:ProductDanyelza', None)
Revenuesus-gaap: Product Or Service, us-gaap: Statement Geographical
us-gaap:Revenues
us-gaap:ProductOrService, us-gaap:ContractWithCustomerSalesChannel
(None, 'us-gaap:SalesChannelThroughIntermediary')
Revenuesus-gaap: Product Or Service, us-gaap: Contract With Customer Sales Channel
us-gaap:OperatingCostsAndExpenses
us-gaap:TypeOfArrangement
(None,)
Operating Costs And Expensesus-gaap: Type Of Arrangement
us-gaap:OperatingCostsAndExpenses
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
(None, 'ymab:LicenseAgreement')
Operating Costs And Expensesus-gaap: Counterparty Name, us-gaap: Type Of Arrangement
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:AwardType
(None,)
Allocated Share Based Compensation Expenseus-gaap: Award Type
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:AwardType, us-gaap:IncomeStatementLocation
('us-gaap:RestrictedStockUnitsRSU', None)
Allocated Share Based Compensation Expenseus-gaap: Award Type, us-gaap: Income Statement Location
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:AccruedLiabilitiesCurrent
us-gaap:TypeOfArrangement
(None,)
Accrued Liabilities Currentus-gaap: Type Of Arrangement
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:Revenues
us-gaap:ProductOrService
(None,)
Revenuesus-gaap: Product Or Service
us-gaap:Revenues
us-gaap:ProductOrService, us-gaap:StatementGeographical
('ymab:ProductDanyelza', None)
Revenuesus-gaap: Product Or Service, us-gaap: Statement Geographical
us-gaap:Revenues
us-gaap:ProductOrService, us-gaap:ContractWithCustomerSalesChannel
(None, 'us-gaap:SalesChannelThroughIntermediary')
Revenuesus-gaap: Product Or Service, us-gaap: Contract With Customer Sales Channel
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:StatementGeographical
('ymab:ProductDanyelza', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Statement Geographical
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:ContractWithCustomerSalesChannel
(None, 'us-gaap:SalesChannelThroughIntermediary')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Contract With Customer Sales Channel